Mabwell (Shanghai) Bioscience Co., Ltd.
SHH: 688062.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Datao Liu
- Employees
- 1,416
- Headquarters
- Shanghai, China
- IPO year
- 2022
- Market cap
- CN¥14.0B
- Website
- www.mabwell.com
Loading 688062…
Loading profile data…Frequently asked questions about 688062
What does Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) do?
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers...
Where does 688062.SS trade?
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) trades on the Shanghai Stock Exchange.
What sector is 688062.SS in?
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mabwell (Shanghai) Bioscience Co., Ltd.?
Datao Liu is the chief executive officer of Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS).
Where is Mabwell (Shanghai) Bioscience Co., Ltd. headquartered?
Mabwell (Shanghai) Bioscience Co., Ltd. is headquartered in China.
Does 688062.SS pay a dividend?
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 688062.SS go public?
Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) completed its initial public offering in 2022.